Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy
Clinical Pharmacology & Therapeutics2019Vol. 106(1), pp. 94–102
Citations Over TimeTop 1% of 2019 papers
Jacob T. Brown, Jeffrey R. Bishop, Katrin Sangkuhl, Erika L. Nurmi, Daniel Mueller, Jean Dinh, Andrea Gaedigk, Teri E. Klein, Kelly E. Caudle, James T. McCracken, José de León, J. Steven Leeder
Abstract
Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
Related Papers
- → Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes(2018)28 cited
- → The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications(2022)5 cited
- → Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6(2019)12 cited
- → CytochromeP450 2D6 and Atomoxetine Metabolism(2010)
- → Physiologically based pharmacokinetic modelling of atomoxetine in the different CYP2D6 genotypes(2018)